RBC Europe’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

RBC Europe’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4	Closed	-$533	–	1196
2020 Q3	$533	Hold	4	–	–	﹤0.01%	1050
2020 Q2	$675	Hold	4	–	–	﹤0.01%	1009
2020 Q1	$575	Hold	4	–	–	﹤0.01%	980
2019 Q4	$1.32K	Hold	4	–	–	﹤0.01%	978
2019 Q3	$2K	Hold	4	–	–	﹤0.01%	967
2019 Q2	$2.43K	Hold	4	–	–	﹤0.01%	972
2019 Q1	$2.44K	Hold	4	–	–	﹤0.01%	988
2018 Q4	$1.46K	Hold	4	–	–	﹤0.01%	1013
2018 Q3	$2.7K	Hold	4	–	–	﹤0.01%	1029
2018 Q2	$3.48K	Hold	4	–	–	﹤0.01%	1011
2018 Q1	$5.03K	Hold	4	–	–	﹤0.01%	944
2017 Q4	$5.98K	Hold	4	–	–	﹤0.01%	923
2017 Q3	$8.19K	Buy	+4	New	+$9.38K	﹤0.01%	878

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

RBC Europe's NBRV Position: Q4 2020 in Review

RBC Europe sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 4 shares — an estimated $533 sold.

RBC Europe first reported a position in NBRV in Q3 2017 and held it in 13 quarters. The position peaked at $8.19K in Q3 2017. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

RBC Europe reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
RBC Europe sold 4 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $533.
RBC Europe first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 13 quarters.
RBC Europe's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $8.19K in Q3 2017.
33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on RBC Europe's 13F filing for Q4 2020, filed 9 Nov 2023.